Study to Test TEV-50717 in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Study Title
- A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Teva Identifier
- TV50717-CNS-30081 | 2019-001807-19
ClinicalTrials.gov Identifier
- NCT04200352
Study Status
- Terminated
Trial Condition(s)
- Cerebral Palsy, Dyskinetic
Interventions
- Drug: TEV-50717
EudractCT Number
- 2019-001807-19
Study Description
Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.
The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP.
The secondary objective of this study is to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of DCP.
Key Participation Requirements
Gender
- Female, Male
Age Range
- 6 Years to 18 Years
Trial Duration
- February 4, 2020 - August 19, 2023
Phase
- Phase 3
Study Type
Interventional
Location - Where to Participate
You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.
